Expression of programmed cell death ligand‑1 protein in germinal center B‑cell‑like and non‑germinal center B‑cell‑like subtypes of diffuse large B‑cell lymphoma

Asrini,Rizka; Ham,Maria Francisca; Asmarinah,Asmarinah; Harahap,Agnes Stephanie; Hardjolukito,Endang S.R.

doi:10.3892/mco.2021.2474

Expression of programmed cell death ligand‑1 protein in germinal center B‑cell‑like and non‑germinal center B‑cell‑like subtypes of diffuse large B‑cell lymphoma

Authors:
- Rizka Asrini
- Maria Francisca Ham
- Asmarinah Asmarinah
- Agnes Stephanie Harahap
- Endang S.R. Hardjolukito
View Affiliations

Affiliations: Master Program of Biomedical Science, Indonesian Medical Education and Research Institute, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia, Human Cancer Research Center, Indonesian Medical Education and Research Institute, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia, Department of Medical Biology, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia
Published online on: December 21, 2021 https://doi.org/10.3892/mco.2021.2474
Article Number: 42

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diffuse large B‑cell lymphoma (DLBCL) is the most common type of non‑Hodgkin lymphoma worldwide. However, there is still limited information on the expression of programmed cell death ligand‑1 (PD‑L1), a type 1 transmembrane protein of immunoglobulin B7/CD28 in the DLBCL subtypes. The present study aimed to identify the expression of PD‑L1 in germinal center B‑cell‑like (GCB) subtype and non‑germinal center B‑cell‑like (non‑GCB) subtype of DLBCL. A total of 40 patient samples (formalin‑fixed paraffin‑embedded tissues) consisting of 20 cases of GCB subtype and 20 cases of non‑GCB subtype of DLBCL were examined. The PD‑L1 protein expressions were evaluated by using immunohistochemical staining in the tumor cells. The results showed a statistically significant difference (P=0.003) between the expression of PD‑L1 in the GCB subtype and the non‑GCB subtype of DLBCL. PD‑L1 expression in the tumor cells were observed in 13 cases (65%) of non‑GCB subtype and in three cases (15%) of the GCB subtype of DLBCL. In conclusion, it was found that the expression of PD‑L1 protein in the tumor cells of the non‑GCB subtype of DLBCL was significantly higher as compared with the tumor cells of the GCB subtype of DLBCL.

View Figures

View References

1	Sethi A, Tandon A, Mishra H and Singh I: Diffuse large B-cell lymphoma: An immunohistochemical approach to diagnosis. J Oral Maxillofac Pathol. 23:284–288. 2019.PubMed/NCBI View Article : Google Scholar
2	Reksodiputro AH: Multicenter epidemiology and survival study of B cell non Hodgkin lymphoma patients in Indonesia. J Blood Disorders Transf. 6(257)2015.
3	Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Firsher RI, Gascoyne RD, Muller-Hermenlink K, Smeland EB, Giltnane JM, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 346:1937–1947. 2002.PubMed/NCBI View Article : Google Scholar
4	Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 403:503–511. 2000.PubMed/NCBI View Article : Google Scholar
5	Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, Wu X, Ma J, Zhou M, Li X, et al: Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 18(10)2019.PubMed/NCBI View Article : Google Scholar
6	Keir ME, Butte MJ, Freeman GJ and Sharpe AH: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 26:677–704. 2008.PubMed/NCBI View Article : Google Scholar
7	Nishimura H, Agata Y, Kawasaki A, Sato M, Imamura S, Minato N, Yagita H, Nakano T and Honjo T: Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. Int Immunol. 8:773–780. 1996.PubMed/NCBI View Article : Google Scholar
8	Xia Y, Jeffrey Medeiros L and Young KH: Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. Biochim Biophys Acta. 1865:58–71. 2016.PubMed/NCBI View Article : Google Scholar
9	Ferrata M, Schad A, Zimmer S, Musholt TJ, Bahr K, Kuenzel J, Becker S, Springer E, Roth W, Weber MM and Fottner C: PD-L1 expression and immune cell infiltration in gastroenteropancreatic (GEP) and Non-GEP neuroendocrine neoplasms with high proliferative activity. Front Oncol. 9(343)2019.PubMed/NCBI View Article : Google Scholar
10	Chen J, Jiang CC, Jin L and Zhang XD: Regulation of PD-L1: A novel role of pro-survival signalling in cancer. Ann Oncol. 27:409–416. 2016.PubMed/NCBI View Article : Google Scholar
11	Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK and Iyer AK: PD-1 and PD-L1 checkpoint signaling inhibition for Cancer immunotherapy: Mechanism, combinations and clinical outcome. Front Pharmacol. 8(561)2017.PubMed/NCBI View Article : Google Scholar
12	Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, Sugita Y, Yufu Y, Choi I, Abe Y, et al: Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood. 126:2193–2201. 2015.PubMed/NCBI View Article : Google Scholar
13	Hu LY, Xu XL, Rao HL, Chen J, Lai RC, Huang HQ, Jiang WQ, Lin TY, Xia ZJ and Cai QQ: Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: A retrospective study. Chin J Cancer. 36(94)2017.PubMed/NCBI View Article : Google Scholar
14	Kwon D, Kim S, Kim PJ, Go H, Nam SJ, Paik JH, Kim YA, Kim TM, Heo DS, Kim CW and Jeon YK: Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumor microenvironments of diffuse large B cell lymphomas. Histopathology. 68:1079–1089. 2016.PubMed/NCBI View Article : Google Scholar
15	Xie M, Huang X, Ye X and Qian W: Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma. Int Immunopharmacol. 77(105999)2019.PubMed/NCBI View Article : Google Scholar
16	Shi Y, Han Y, Yang J, Liu P, He X, Zhang C, Zhou S, Zhou L, Qin Y, Song Y, et al: Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China. Chin J Cancer Res. 31:152–161. 2019.PubMed/NCBI View Article : Google Scholar
17	Fang X, Xiu B, Yang Z, Qiu W, Zhang L, Zhang S, Wu Y, Zhu X, Chen X, Xie S, et al: The expression and clinical relevance of PD-1, PD-L1 and TP63 in patients with diffuse large B-cell lymphoma. Medicine (Baltimore). 96(e6398)2017.PubMed/NCBI View Article : Google Scholar